
Matthew R Gardner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8556636/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature, 2015, 519, 87-91.	27.8	265
2	Associating HIV-1 envelope glycoprotein structures with states on theÂvirus observed by smFRET. Nature, 2019, 568, 415-419.	27.8	156
3	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. PLoS Pathogens, 2021, 17, e1009501.	4.7	97
4	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. Molecular Therapy, 2019, 27, 650-660.	8.2	42
5	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. Science Translational Medicine, 2019, 11, .	12.4	35
6	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. MBio, 2020, 11, .	4.1	27
7	Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants. Journal of Virology, 2012, 86, 12417-12421.	3.4	24
8	eCD4-lg promotes ADCC activity of sera from HIV-1-infected patients. PLoS Pathogens, 2017, 13, e1006786.	4.7	24
9	eCD4-Ig Variants That More Potently Neutralize HIV-1. Journal of Virology, 2018, 92, .	3.4	22
10	Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. Molecular Therapy, 2018, 26, 1277-1286.	8.2	22
11	Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. Frontiers in Cellular and Infection Microbiology, 2020, 10, 176.	3.9	22
12	eCD4-lg Limits HIV-1 Escape More Effectively than CD4-lg or a Broadly Neutralizing Antibody. Journal of Virology, 2019, 93, .	3.4	19
13	Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Current Opinion in HIV and AIDS, 2017, 12, 294-301.	3.8	18
14	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. PLoS Pathogens, 2018, 14, e1007238.	4.7	18
15	A Double-Mimetic Peptide Efficiently Neutralizes HIV-1 by Bridging the CD4- and Coreceptor-Binding Sites of gp120. Journal of Virology, 2014, 88, 3353-3358.	3.4	14
16	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. Journal of Virology, 2016, 90, 7822-7832.	3.4	14
17	High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes. Molecular Therapy - Methods and Clinical Development, 2022, 24, 199-206.	4.1	13
18	Direct Expression and Validation of Phage-selected Peptide Variants in Mammalian Cells. Journal of Biological Chemistry, 2013, 288, 18803-18810.	3.4	10

#	Article	IF	CITATIONS
19	Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. Journal of Virology, 2017, 91, .	3.4	3
20	A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. Journal of Virology, 2019, 93, .	3.4	2
21	Estimation of the in vivo neutralization potency of eCD4lg and conditions for AAV-mediated production for SHIV long-term remission. Science Advances, 2022, 8, eabj5666.	10.3	1